SCHEMBL6710797

SCHEMBL6710797

CCOC(=O)c1cn(-c2ccccc2C)c2ccc(CN3CCOCC3)cc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HPGD P15428 1/20 0.47
PIM1 P11309 1/20 0.47
IRAK1 P51617 1/20 0.47
CAMK2B Q13554 1/20 0.47
CAMK2G Q13555 1/20 0.47
CAMK2D Q13557 1/20 0.47
PIM3 Q86V86 1/20 0.47
NPSR1 Q6W5P4 5/20 0.44
TSHR P16473 4/20 0.44
LMNA P02545 4/20 0.43
MAPT P10636 3/20 0.43
MAPK1 P28482 1/20 0.43
STAT3 P40763 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TNKS O95271 1/20 0.42
ROCK2 O75116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6708329 0.91 ALDH1A1 (0.45) ALDH1A1KDM4EHSD17B10HPGDPIM1
SCHEMBL27595784 0.90 ALDH1A1 (0.45) ALDH1A1KDM4EHSD17B10HPGDPIM1
SCHEMBL6709496 0.89 NPSR1 (0.51) ALDH1A1KDM4EHSD17B10HPGDPIM1
SCHEMBL6709588 0.85 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10HPGDNPSR1
SCHEMBL6712544 0.84 NPSR1 (0.51) ALDH1A1KDM4EHSD17B10HPGDPIM1
SCHEMBL6814201 0.84 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10HPGDNPSR1
SCHEMBL6709410 0.84 NPC1 (0.48) ALDH1A1KDM4EHSD17B10HPGDNPSR1
SCHEMBL17896908 0.84 GRM2 (0.57) ALDH1A1KDM4EHSD17B10HPGDNPSR1
SCHEMBL6709614 0.83 NPSR1 (0.46) ALDH1A1KDM4EHSD17B10HPGDNPSR1
SCHEMBL6710770 0.83 NPSR1 (0.44) ALDH1A1KDM4EHSD17B10HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents SCHNUTE MARK E (US) 2004-02-05 US disclosed
US-6653307-B2 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors PHARMACIA & UPJOHN COMPANY 2003-11-25 US disclosed
EP-1292575-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-19 EP disclosed
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2001098275-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, IRF3 ALDH1A1 668/4885KDM4E 314/4885HSD17B10 3255/4885
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, IRF3, ZC3HAV1L ALDH1A1 463/4885KDM4E 178/4885HSD17B10 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.